Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The approach involves in-depth molecular simulations of the target protein by itself and in complex with its primary partner proteins, paired with ensemble virtual screening that factors in conformational mobility in both the unbound and complex states. The tentative binding pockets are identified at the protein-protein interaction interface and in distant allosteric areas, aiming to capture the full range of mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O60934

UPID:
NBN_HUMAN

ALTERNATIVE NAMES:
Cell cycle regulatory protein p95; Nijmegen breakage syndrome protein 1

ALTERNATIVE UPACC:
O60934; B2R626; B2RNC5; O60672; Q32NF7; Q53FM6; Q63HR6; Q7LDM2

BACKGROUND:
The protein Nibrin, identified as a cell cycle regulatory protein p95, is integral to the MRN complex, which is critical for the cellular response to DNA damage and maintaining genomic stability. Nibrin's functions include DNA damage sensing, signal transduction, and effectuation, crucial for DNA integrity. It also plays a role in telomere length maintenance and cell cycle checkpoints.

THERAPEUTIC SIGNIFICANCE:
Given Nibrin's association with significant diseases like Nijmegen breakage syndrome, breast cancer, and aplastic anemia, its study offers promising avenues for therapeutic development. The protein's critical role in DNA repair and cell cycle regulation makes it a potential target for innovative treatments aimed at enhancing genomic stability.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.